Cholesterol and ApoB: The Particles That Build Plaque Over a Lifetime

A standard panel reports total cholesterol, LDL ('low-density lipoprotein') cholesterol, HDL ('high-density lipoprotein') cholesterol and triglycerides. LDL particles carry cholesterol out to the tissues; HDL carries it back. It is the LDL — and other apolipoprotein-B-containing particles — that can lodge in artery walls and seed plaque.

ApoB is a newer number worth knowing: exactly one ApoB protein rides on each atherogenic particle, so an ApoB measurement is essentially a direct count of the particles that cause plaque, rather than an estimate of the cholesterol they carry (Sniderman et al., 2019).

For decades the LDL–heart-disease link could be dismissed as mere association. That case is now closed. Converging evidence from genetics (people born with lifelong low LDL have very low heart-disease rates), long-term observation, and randomised drug trials shows that LDL/ApoB particles cause atherosclerotic cardiovascular disease — a formal consensus of the European Atherosclerosis Society (Ference et al., 2017).

The effect is cumulative: it is the lifetime exposure — how high, for how long — that builds plaque, much like pack-years for smoking. This is why lowering LDL earlier and for longer yields more benefit than lowering it late.

LDL-cholesterol can understate risk in common situations — high triglycerides, diabetes, or many small dense LDL particles — where a 'normal' LDL-C still hides a high particle count. Because ApoB counts particles directly, it tends to predict cardiovascular risk at least as well as, and often better than, LDL-C or non-HDL cholesterol (Sniderman et al., 2011).

This is why lipid specialists increasingly favour ApoB (or non-HDL cholesterol as a cheaper stand-in) for judging risk, and modern guidelines list ApoB as a preferred measure especially when triglycerides are raised (Mach et al., 2020).

Diet and lifestyle move these numbers meaningfully: reducing saturated fat, adding soluble fibre, staying physically active, and reaching a healthy weight all lower LDL/ApoB, while regular activity and lower refined-carbohydrate intake improve triglycerides and HDL. For many people lifestyle alone is enough.

When risk is higher, LDL-lowering medication (statins first) is among the best-evidenced interventions in all of medicine: a large meta-analysis of over 170,000 people found that each reduction in LDL cut the rate of major vascular events proportionally, and safely (Cholesterol Treatment Trialists' Collaboration, 2010). The practical step is to get a lipid panel — ideally including ApoB — and discuss your target with a qualified professional, since the right goal depends on your overall risk.